NASDAQ : CTSO
Cytosorbents Corporation — Key statistics
Healthcare · Medical Devices · United States
Last price 4.54 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 14.31M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 14.31M |
| Enterprise Value | 39.32M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 3.15M |
| Shares Outstanding | 3.15M |
| Shares Change (YoY) | +8.00% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 11.78% |
| Owned by Institutions (%) | 25.09% |
| Float | 2.78M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.38 |
| Forward PS | 0.34 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.66 |
| Quick Ratio | 0.47 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.78 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -336.21% |
| Return on Assets (ROA) | -17.12% |
| Return on Invested Capital (ROIC) | -21.86% |
| Return on Capital Employed (ROCE) | -84.46% |
| Weighted Average Cost of Capital (WACC) | 9.68% |
| Revenue Per Employee | $288,496 |
| Profits Per Employee | -$141,194 |
| Employee Count | 129 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 2.86 |
Taxes
| Measure | Value |
|---|
| Income Tax | -401,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.48 |
| 52-Week Price Change | -70.97% |
| 50-Day Moving Average | 5.30 |
| 200-Day Moving Average | 9.49 |
| Relative Strength Index (RSI) | 47.86 |
| Average Volume (20 Days) | 72,641 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 114,402 |
| Short Previous Month | 123,890 |
| Short % of Shares Out | 3.63% |
| Short % of Float | 4.12% |
| Short Ratio (days to cover) | 10.48 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 37.22M |
| Gross Profit | 26.65M |
| Operating Income | -11.77M |
| Pretax Income | -18.62M |
| Net Income | -18.21M |
| EBITDA | -10.35M |
| EBIT | -11.77M |
| Loss Per Share | -$5.82 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 4.41M |
| Total Debt | 29.43M |
| Net Cash | -25.01M |
| Net Cash Per Share | -$7.94 |
| Equity (Book Value) | -751,000 |
| Book Value Per Share | -0.24 |
| Working Capital | -8.29M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -9.15M |
| Capital Expenditures | -150,000 |
| Depreciation & Amortization | 1.42M |
| Net Borrowing | 2.48M |
| Free Cash Flow | -9.30M |
| FCF Per Share | -$2.95 |
Margins
| Measure | Value |
|---|
| Gross Margin | 71.61% |
| Operating Margin | -31.63% |
| Pretax Margin | -50.02% |
| Profit Margin | -48.94% |
| EBITDA Margin | -27.81% |
| EBIT Margin | -31.63% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.00% |
| Shareholder Yield | n/a |
| Earnings Yield | -128.25% |
| FCF Yield | -64.99% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $12.25 |
| Price Target Difference | 169.82% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 11.66% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 8, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -11.45 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |